Lyell Immunopharma, Inc. Common Stock

Day range

—

Open

—

Prev close

$15.00

Volume

1.57K

Market cap

$368.78M

Shares out

24.5M

P/E

—

P/S

13658.65

P/B

1.58

P/FCF

—

ROE

-106.3%

ROA

-79.9%

Debt/Equity

0.00

Div yield

0.00%

As of Nov 5, 2026

• Quarterly earningsNov 4, 2026

  On November 4, 2026, Lyell Immunopharma, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026.

• Private placementNov 4, 2026

  On November 3, 2026, Lyell Immunopharma, Inc. entered into a Securities Purchase Agreement with certain institutional accredited investors, pursuant to which the Company agreed to sell and issue an aggregate of 7,428,040 shares of the Company's common stock at a purchase price of $10.77 per Share, in a private placement transaction. The total gross proceeds from the Private Placement, before expenses, are expected to be approximately $80.0 million.

• Product or service launchSep 10, 2026

  Lyell Immunopharma, Inc. issued a press release regarding "the completion of the technology transfer for LYL273 to the Company's LyFE Manufacturing Facility™ in Bothell, Washington" and described LYL273 as the Company's "next-generation guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate."

• Executive compensation changeMar 9, 2026

  Pursuant to the offer letter, Ms. Shah is entitled to receive an initial annual base salary of $500,000 and a target annual bonus of up to 50% of her base salary. In addition, Ms. Shah will receive a stock option for 140,000 shares of common stock of the Company, with an exercise price equal to the fair market value of the common stock on the date of grant, to be granted under the Company's 2021 Equity Incentive Plan.

• Clinical trial resultsDec 8, 2025

  Translational data from the ongoing Phase 1/2 clinical trial showed that ronde-cel manufactured with CD62L enrichment achieved robust expansion and high expression of memory-related genes after infusion in patients with LBCL. Ronde-cel had up to a three-fold higher expansion in patients after infusion compared to the expansion of approved CD19 CAR T-cell products.

Days to cover

7.8

Short interest

1.4M

Avg volume

178.11K

As of Oct 15, 2026 · reported to FINRA twice monthly.

• Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
  positiveGlobeNewswire Inc.· Jun 12, 2026
• Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
  positiveGlobeNewswire Inc.· Jun 8, 2026
• Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
  positiveGlobeNewswire Inc.· Mar 9, 2026
• Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors
  positiveGlobeNewswire Inc.· Dec 9, 2025
• Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
  positiveGlobeNewswire Inc.· Dec 7, 2025